# Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone

> **NCT01626833** · PHASE2,PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 15 (actual)

## Conditions studied

- Anorexia Nervosa
- Interruption of Growth
- Delayed Puberty
- Osteopenia With Failure of Acquisition of Bone Mass

## Interventions

- **DRUG:** SOMATROPINE* : Norditropine® simplexx®
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01626833
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2021-03
- **Final completion:** 2021-03
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01626833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01626833, "Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01626833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*